GlassScriptPhysician profile
Mamoon Rasheed
NPI 1386992246
$3,569.92
in general payments reported to CMS, 2019-2025
30 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $118 · 2021: $136 · 2022: $215 · 2023: $803 · 2024: $1,012 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970 · Education: $26.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.81 |
| Education | $26.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $710.80 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $523.89 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $264.36 | 2023-2025 | Monoferric |
| Abbvie INC. | $238.67 | 2025 | |
| Horizon Therapeutics Plc | $211.22 | 2020-2023 | Krystexxa |
| Amgen INC. | $205.13 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Novo Nordisk INC | $149.95 | 2022-2025 | Ozempic, Rybelsus |
| Vantive US Healthcare LLC | $149.11 | 2025 | Renal - Pd |
| Fresenius USA Marketing, INC. | $140.43 | 2019-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $137.33 | 2020-2025 | Benlysta |
| Vifor Pharma, INC. | $96.02 | 2020-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $82.80 | 2022-2024 | Rayaldee |
| Nxstage Medical, INC. | $81.03 | 2023 | Liberty Select Cycler |
| Astrazeneca Pharmaceuticals LP | $67.99 | 2019-2023 | Lokelma |
| Alexion Pharmaceuticals, INC. | $64.64 | 2022-2024 | Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $62.55 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $49.79 | 2020-2025 | Voyxact |
| Recor Medical INC | $44.98 | 2024 | Paradise Renal Denervation System |
| Daiichi Sankyo INC. | $35.86 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.66 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $33.46 | 2025 | Terlivaz |
| Ardelyx, INC. | $29.21 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.54 | 2025 | Jardiance |
| Cormedix INC. | $25.42 | 2025 | Defencath |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $16.80 | 2022 | |
| Lilly USA, LLC | $16.60 | 2024 | Jardiance |
| Genentech USA, INC. | $15.42 | 2019 | |
| Akebia Therapeutics INC | $14.87 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamoon Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.